BACKGROUND: Hormone ablation therapy is the standard therapy for prostate cancer; however, there are large individual differences in the duration of response to the therapy. We investigated, in this retrospective multicenter study, the association between genetic polymorphic variations in steroidogenesis-related genes and the risk of progression to castration-resistant prostate cancer (CRPC) in Japanese patients after androgen deprivation therapy. METHODS: Two hundred and fourteen Japanese patients with prostate cancer who were receiving androgen deprivation therapy were enrolled in this study. We investigated 22 single-nucleotide polymorphisms (SNPs) from 8 genes related to steroidogenesis. The SNPs were assayed by polymerase chain reaction (PCR)-based methods. The different genotypes in this cohort were analyzed according to a case-control status of progression to CRPC at the median duration of hormonal therapy. A logistic regression method with adjustments for patients' characteristics was applied for the analysis.After applying the logistic regression method, we performed Cox regression analysis, following Kaplan-Meier and log-rank analyses. RESULTS: In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05). Cox regression analysis for these SNPs showed an association of risk of progression to CRPC with the rs743572 genotype (p = 0.02, odds ratio [OR] 0.43, 95 % confidence interval [CI] 0.22-0.85). CONCLUSION: The genetic backgrounds for CYP17A1 genes could influence the progression of prostate cancer to CRPC after androgen deprivation therapy.
BACKGROUND: Hormone ablation therapy is the standard therapy for prostate cancer; however, there are large individual differences in the duration of response to the therapy. We investigated, in this retrospective multicenter study, the association between genetic polymorphic variations in steroidogenesis-related genes and the risk of progression to castration-resistant prostate cancer (CRPC) in Japanese patients after androgen deprivation therapy. METHODS: Two hundred and fourteen Japanese patients with prostate cancer who were receiving androgen deprivation therapy were enrolled in this study. We investigated 22 single-nucleotide polymorphisms (SNPs) from 8 genes related to steroidogenesis. The SNPs were assayed by polymerase chain reaction (PCR)-based methods. The different genotypes in this cohort were analyzed according to a case-control status of progression to CRPC at the median duration of hormonal therapy. A logistic regression method with adjustments for patients' characteristics was applied for the analysis.After applying the logistic regression method, we performed Cox regression analysis, following Kaplan-Meier and log-rank analyses. RESULTS: In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05). Cox regression analysis for these SNPs showed an association of risk of progression to CRPC with the rs743572 genotype (p = 0.02, odds ratio [OR] 0.43, 95 % confidence interval [CI] 0.22-0.85). CONCLUSION: The genetic backgrounds for CYP17A1 genes could influence the progression of prostate cancer to CRPC after androgen deprivation therapy.
Authors: H Kakinuma; N Tsuchiya; T Habuchi; C Ohyama; S Matsuura; L Wang; A Nakamura; T Kato Journal: Prostate Cancer Prostatic Dis Date: 2004 Impact factor: 5.554
Authors: Nina Mononen; Eija H Seppälä; Priya Duggal; Ville Autio; Tarja Ikonen; Pekka Ellonen; Juha Saharinen; Janna Saarela; Mauno Vihinen; Teuvo L J Tammela; Olli Kallioniemi; Joan E Bailey-Wilson; Johanna Schleutker Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: Alison H M Reid; Gerhardt Attard; Daniel C Danila; Nikhil Babu Oommen; David Olmos; Peter C Fong; L Rhoda Molife; Joanne Hunt; Christina Messiou; Christopher Parker; David Dearnaley; Joost F Swennenhuis; Leon W M M Terstappen; Gloria Lee; Thian Kheoh; Arturo Molina; Charles J Ryan; Eric Small; Howard I Scher; Johann S de Bono Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: Robert W Ross; William K Oh; Wanling Xie; Mark Pomerantz; Mari Nakabayashi; Oliver Sartor; Mary-Ellen Taplin; Meredith M Regan; Philip W Kantoff; Matthew Freedman Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Prevathe Poniah; Zahurin Mohamed; Yamunah Devi Apalasamy; Shamsul Mohd Zain; Shanggar Kuppusamy; Azad Ha Razack Journal: Int J Clin Exp Med Date: 2015-10-15
Authors: Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi Journal: Biochim Biophys Acta Date: 2014-09-06
Authors: Inmaculada Robles-Fernandez; Luis Javier Martinez-Gonzalez; Manrique Pascual-Geler; Jose Manuel Cozar; Ignacio Puche-Sanz; Maria Jose Serrano; Jose Antonio Lorente; Maria Jesus Alvarez-Cubero Journal: PLoS One Date: 2017-10-05 Impact factor: 3.240